MA27980A1 - Nouvelle composition - Google Patents

Nouvelle composition

Info

Publication number
MA27980A1
MA27980A1 MA28777A MA28777A MA27980A1 MA 27980 A1 MA27980 A1 MA 27980A1 MA 28777 A MA28777 A MA 28777A MA 28777 A MA28777 A MA 28777A MA 27980 A1 MA27980 A1 MA 27980A1
Authority
MA
Morocco
Prior art keywords
composition
dosage form
drug
pharmaceutically acceptable
release
Prior art date
Application number
MA28777A
Other languages
English (en)
Inventor
John Francis Hoke
Martini Luigi
Vincenzo Re
Mark Edward Sale
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27980(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of MA27980A1 publication Critical patent/MA27980A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition pour la libération d'une base faible pendant une période de temps prolongée Une forme posologique orale comprenant une première composition et une seconde composition, chaque composition comprenant une base faible pharmaceutiquement acceptable, notamment le Composé A ou un de ses sels ou produits de solvatation pharmaceutiquement acceptables ("le médicament"), et un support pharmaceutiquement acceptable à cette fin, dans laquelle les première et seconde compositions sont conçues pour libérer le médicament à des vitesses de libération différentes par administration de telle sorte que la vitesse de libération du médicament par la forme posologique soit substantiellement indépendante du pH ; un procédé pour la préparation d'une telle forme posologique et l'utilisation d'une telle forme posologique en médecine.
MA28777A 2003-08-07 2006-02-07 Nouvelle composition MA27980A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49338803P 2003-08-07 2003-08-07

Publications (1)

Publication Number Publication Date
MA27980A1 true MA27980A1 (fr) 2006-07-03

Family

ID=34135242

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28777A MA27980A1 (fr) 2003-08-07 2006-02-07 Nouvelle composition

Country Status (25)

Country Link
US (1) US20070134326A1 (fr)
EP (1) EP1660049A2 (fr)
JP (1) JP2007501773A (fr)
KR (1) KR20060113650A (fr)
CN (2) CN1832729A (fr)
AP (1) AP2006003488A0 (fr)
AR (1) AR045330A1 (fr)
AU (1) AU2004262926B2 (fr)
BR (1) BRPI0413374A (fr)
CA (1) CA2534546A1 (fr)
EA (2) EA011508B1 (fr)
EC (1) ECSP066318A (fr)
IL (1) IL173176A0 (fr)
IS (1) IS8336A (fr)
MA (1) MA27980A1 (fr)
MX (1) MXPA06001407A (fr)
NO (1) NO20061018L (fr)
NZ (1) NZ544696A (fr)
OA (1) OA13230A (fr)
PE (1) PE20050335A1 (fr)
SG (1) SG145717A1 (fr)
TW (1) TW200517127A (fr)
UY (1) UY28457A1 (fr)
WO (1) WO2005013935A2 (fr)
ZA (1) ZA200600521B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1686967A4 (fr) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
GB0502479D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
SI2395840T1 (sl) 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
CN103948557A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
WO2001082867A2 (fr) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. Formulation de noyaux
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada

Also Published As

Publication number Publication date
WO2005013935A3 (fr) 2005-07-14
JP2007501773A (ja) 2007-02-01
TW200517127A (en) 2005-06-01
EP1660049A2 (fr) 2006-05-31
IS8336A (is) 2006-03-02
UY28457A1 (es) 2005-03-31
AR045330A1 (es) 2005-10-26
AU2004262926B2 (en) 2009-11-19
ZA200600521B (en) 2007-01-31
EA011508B1 (ru) 2009-04-28
EA200701409A1 (ru) 2007-10-26
NZ544696A (en) 2009-03-31
CN101239047A (zh) 2008-08-13
US20070134326A1 (en) 2007-06-14
ECSP066318A (es) 2006-07-28
CN1832729A (zh) 2006-09-13
MXPA06001407A (es) 2006-05-15
BRPI0413374A (pt) 2006-10-17
AU2004262926A1 (en) 2005-02-17
IL173176A0 (en) 2006-06-11
PE20050335A1 (es) 2005-06-01
EA200600377A1 (ru) 2006-08-25
AP2006003488A0 (en) 2006-02-28
SG145717A1 (en) 2008-09-29
WO2005013935A2 (fr) 2005-02-17
OA13230A (en) 2006-12-13
KR20060113650A (ko) 2006-11-02
NO20061018L (no) 2006-03-01
CA2534546A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
TNSN94078A1 (fr) Nouvelle formule pharmaceutique
DK0688214T3 (da) Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
JP2005515966A5 (fr)
WO2005065069A3 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
IL142801A0 (en) Pharmaceutical compositions containing an adenosine analog
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
RS50262B (sr) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
DK1365749T3 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til anvendelse i blöde gelformuleringer
MA27980A1 (fr) Nouvelle composition
AP2003002763A0 (en) Controlled release formulations for oral administration
HUP0301487A2 (hu) Piranon proteáz inhibitorok orális adagolású önemulgeáló formulációi
MX2007006635A (es) Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
MA27996A1 (fr) Nouvelle composition comprenant la rosiglitazone et un autre agent antidiabetique
AP2001002119A0 (en) Sertraline oral concentrate.
GEP20043377B (en) Pharmaceutical Complex
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények
DE50010973D1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
TNSN00015A1 (fr) Nouveaux sels de morpholinobenzamide
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
WO2002055062A3 (fr) Comprime pharmaceutique comprenant du mesylate de paroxetine
GB9819685D0 (en) Anti-inflammatory pharmaceutical formulations